Opinion

Video

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.

Video content above is prompted by the following question(s):

  1. What future research is needed to further support decision-making when using CDK4/6 inhibitors for early breast cancer?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Rebecca Chacko, MD.
Rebecca Chacko, MD, breast medical oncologist at Henry Ford
4 experts in this video
4 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo